Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade

As we look forward to the bright future of immune checkpoint blockade (ICB) therapy, there is still lacking a pharmacokinetic marker to understand the inter-individual differences in ICB response. ICB therapy is based on IgG antibodies that share the same homeostatic pathway with serum albumin. Ther...

Descripción completa

Detalles Bibliográficos
Autor principal: Zheng, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772729/
https://www.ncbi.nlm.nih.gov/pubmed/36600664
http://dx.doi.org/10.1136/jitc-2022-005670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772729/
https://www.ncbi.nlm.nih.gov/pubmed/36600664
http://dx.doi.org/10.1136/jitc-2022-005670

Ejemplares similares